**Table 1.** Patient and transplant characteristics

|  |  |
| --- | --- |
| Age, median yr, (range) | 15.4 (0.6-27.2) |
| Gender Male, n (%) | 17 (74) |
| Race/Ethnicity, n (%) |  |
| Hispanic | 8 (35) |
| African American | 2 (9) |
| Asian American  White | 1 (4)  12 (52) |
| Disease n (%) |  |
| AML\* | **17** |
| CR1/MRD- | 7 (41) |
| CR1/MRD+ | 6 (35) |
| CR2/MRD- | 2 (12) |
| CR2/MDR+ | 1 (6) |
| NR | 1 (6) |
| MDS | **4** |
| untreated | 4 (100) |
| CML | **2** |
| Cytogenetics, n (%) |  |
| AML/MDS | **21** |
| del(7q) | 3 (14) |
| del(5q) | 1 (5) |
| KMT2A | 4 (19) |
| FLT3-ITD | 4 (19) |
| t(8;21) | 2 (10) |
| inv(16) | 2 (10) |
| other | 3 (14) |
| NA | 2 (10) |
| Therapy associated AML/MDS | **4** |
| Disease risk index, n (%) |  |
| AML/MDS | **21** |
| Low | 2 (10) |
| Intermediate | 15 (71) |
| High | 3 (14) |
| Very High | 1 (5) |
| CML | **2** |
| s/p AP | 1 (50) |
| T315I mutation | 1 (50) |
| Donor and graft |  |
| HAPLO BM | 11 (48) |
| MSD PB | 7 (30) |
| URD PB | 2 (9) |
| UCB | 3 (13) |
| GvHD prophylaxis |  |
| HAPLO |  |
| PT-CY, MMF, Tacro | 7 (30) |
| PT-CY/BEN, MMF, Tacro | 4 (17) |
| MSD |  |
| CSA, MTX | 7 (30) |
| URD |  |
| CSA, MTX | 2 (9) |
| UCB |  |
| CSA, MMF | 3 (13) |
| HLA match |  |
| HAPLO | **11** |
| 5/10 | 5 (45) |
| 6/10 | 5 (45) |
| 7/10 | 1 (9) |
| MSD | **7** |
| URD | **2** |
| 10/10 | 2 (100) |
| UCB | **3** |
| 5/6 | 1 (33) |
| 4/6, 4/6 | 2 (67) |

AML= acute myeloid leukemia, \*=includes one acute undifferentiated leukemia, MDS=myelodysplastic syndrome,

CML= chronic myeloid leukemia, CR= complete remission, MRD= minimal residual disease, NR= not in remission,

NA= no abnormalities, AP= accelerated phase, MSD= matched sibling donor, HAPLO= haploidentical, URD= unrelated donor,

UCB= umbilical cord blood, PB= peripheral blood stem cells, BM= bone marrow stem cells, CSA= cyclosporine A,

MTX= methotrexate, MMF= mycophenolate mofetil, Tacro= tacrolimus, CY= cyclophosphamide, BEN= bendamustine